Free Trial

Eledon Pharmaceuticals (ELDN) News Today

Eledon Pharmaceuticals logo
$2.80 -0.07 (-2.44%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$2.93 +0.13 (+4.64%)
As of 06/16/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELDN Latest News

Eledon Pharmaceuticals, Inc. stock logo
Bank of America Corp DE Increases Stock Holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Bank of America Corp DE boosted its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 1,295.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 95,142 shares of the company's stock after purchasing an additional 88,326 shares du
Eledon Pharmaceuticals, Inc. stock logo
Millennium Management LLC Invests $490,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Millennium Management LLC bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 118,861 shares of the company's stock, valued at approximately $490,000. Millennium Managem
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals (NASDAQ:ELDN) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen cut Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday.
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 12.3% in May
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 1,570,000 shares, a decline of 12.3% from the April 30th total of 1,790,000 shares. Based on an average trading volume of 221,700 shares, the days-to-cover ratio is presently 7.1 days. Currently, 3.0% of the company's shares are short sold.
Eledon Pharmaceuticals, Inc. stock logo
Jane Street Group LLC Makes New $504,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Jane Street Group LLC purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 122,275 shares of the company's stock, value
Eledon Pharmaceuticals, Inc. stock logo
Woodline Partners LP Boosts Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Woodline Partners LP increased its stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 98.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,671,822 shares of the company's stock after acquiring an additional 828,930 sha
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals (NASDAQ:ELDN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday.
Eledon Pharmaceuticals, Inc. stock logo
1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by AWM Investment Company Inc.
AWM Investment Company Inc. acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,100,473 shares of the company's stock, valued at approximately $4,534,
Eledon Pharmaceuticals, Inc. stock logo
Equities Analysts Offer Predictions for ELDN Q2 Earnings
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Noble Financial issued their Q2 2025 EPS estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. Noble Financial analyst R. Leboyer anticipates that the company will earn ($0.22) per
Eledon Pharmaceuticals, Inc. stock logo
Frazier Life Sciences Management L.P. Invests $4.85 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Frazier Life Sciences Management L.P. purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,176,735 shares of
Eledon Pharmaceuticals, Inc. stock logo
Zimmer Partners LP Has $3.09 Million Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Zimmer Partners LP lessened its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 47.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 750,000 shares of the company's stock after selling 684,727 shares during th
Eledon Pharmaceuticals, Inc. stock logo
Point72 Asset Management L.P. Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Point72 Asset Management L.P. purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,095,000 shares of the company's stock, valued at approximately $4,511,000. Po
Eledon Pharmaceuticals, Inc. stock logo
Velan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Velan Capital Investment Management LP bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 323,973 shares of the company
Eledon Pharmaceuticals, Inc. stock logo
FY2025 EPS Estimates for ELDN Boosted by Cantor Fitzgerald
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Eledon Pharmaceuticals in a report released on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company wil
Eledon Pharmaceuticals, Inc. stock logo
Q2 EPS Estimate for Eledon Pharmaceuticals Lifted by Analyst
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a report issued on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company will
Eledon Pharmaceuticals, Inc. stock logo
Sphera Funds Management LTD. Buys 1,254,298 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Sphera Funds Management LTD. raised its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 96.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,551,619 shares
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Shares Purchased by Ensign Peak Advisors Inc
Ensign Peak Advisors Inc boosted its holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 185.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,264,919 shares of the company's stock
Eledon Pharmaceuticals, Inc. stock logo
Alyeska Investment Group L.P. Increases Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Alyeska Investment Group L.P. grew its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 86.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 933,475 shares of the company's stock after buying an additional 433,475 shares during the pe
Eledon Pharmaceuticals, Inc. stock logo
Marshall Wace LLP Invests $331,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Marshall Wace LLP acquired a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 80,431 shares of the company's stock, valued at approximately $331,000. Marshall
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Increase in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,750,000 shares, a growth of 19.9% from the March 31st total of 1,460,000 shares. Approximately 3.3% of the company's stock are short sold. Based on an average daily volume of 233,300 shares, the days-to-cover ratio is currently 7.5 days.
Eledon Pharmaceuticals, Inc. stock logo
Allostery Investments LP Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Allostery Investments LP purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the co
Eledon Pharmaceuticals, Inc. stock logo
683 Capital Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
683 Capital Management LLC bought a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 154,960 shares of the company's stock, valued at appr
Eledon Pharmaceuticals, Inc. stock logo
235,750 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by Acuta Capital Partners LLC
Acuta Capital Partners LLC acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 235,750 shares of the company's stock, valued at approxim
Eledon Pharmaceuticals, Inc. stock logo
RA Capital Management L.P. Acquires New Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
RA Capital Management L.P. bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,566,338 shares of the company's stock, value
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday
Eledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eledon-pharmaceuticals-inc-stock/)
Eledon Pharmaceuticals, Inc. stock logo
Boothbay Fund Management LLC Buys New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Boothbay Fund Management LLC purchased a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 341,923 shares of the company's stock, valued
Eledon Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Raises Stock Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Nantahala Capital Management LLC lifted its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 91.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,147,946 shares of the company's sto
Eledon Pharmaceuticals, Inc. stock logo
First Light Asset Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
First Light Asset Management LLC bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,328,768 shares of the company's stock, va
Eledon Pharmaceuticals, Inc. stock logo
Geode Capital Management LLC Buys 285,043 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Geode Capital Management LLC lifted its stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 75.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 663,101 shares of the company's stock after purchasing an
Eledon Pharmaceuticals, Inc. stock logo
Blue Owl Capital Holdings LP Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,959,912 shares of the company's stock, valued at approximately $8,075,000.
Eledon Pharmaceuticals, Inc. stock logo
EAM Investors LLC Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)
EAM Investors LLC purchased a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 109,555 shares of the company's stock, valued at
Eledon Pharmaceuticals, Inc. stock logo
Cantor Fitzgerald Weighs in on ELDN FY2025 Earnings
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the compa
Eledon Pharmaceuticals, Inc. stock logo
Leerink Partnrs Has Negative Outlook of ELDN FY2025 Earnings
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now anticipates that the compa
Eledon Pharmaceuticals, Inc. stock logo
Equities Analysts Set Expectations for ELDN Q1 Earnings
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.28) per
Guggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Earnings Results, Misses Estimates By $0.30 EPS
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.30).
Eledon Pharmaceuticals, Inc. stock logo
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's Why
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.4% - Should You Sell?
Eledon Pharmaceuticals, Inc. stock logo
Leerink Partnrs Has Pessimistic View of ELDN Q4 Earnings
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.32) per sh
Get Eledon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.

ELDN Media Mentions By Week

ELDN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ELDN
News Sentiment

1.76

0.90

Average
Medical
News Sentiment

ELDN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ELDN Articles
This Week

2

2

ELDN Articles
Average Week

Get Eledon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ELDN) was last updated on 6/17/2025 by MarketBeat.com Staff
From Our Partners